EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Japan Society of Gynecologic Oncology 2023 guidelines for treatment of uterine body neoplasm

Tohru Morisada iD, Yoichi Kobayashi iD, Satoru Nagase iD, Tsukasa Baba iD, Hideki Tokunaga iD, Hidemichi Watari iD, Munetaka Takekuma iD, Yasuhisa Terao iD, Yoshito Terai iD, Hiroaki Kajiyama iD, Mikiko Asai-Sato iD, Kazuhiro Takehara iD und 6 weitere

Journal of Gynecologic Oncology · 2025

DOI: 10.3802/jgo.2025.36.e119 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Tohru Morisada und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Kyorin University, Tokyo, Japan. Hauptthemen laut MEDLINE: Uterine Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Japan Society of Gynecologic Oncology (JSGO) guideline for the treatment of uterine body neoplasm are revised from the 2018 guideline. This guideline aimed to provide standardized care for uterine body neoplasm, indicate appropriate current treatment methods for uterine body neoplasm, minimize variances in treatment methods among institutions, improve disease prognosis and treatment safety, reduce the economic and psychosomatic burden on patients by promoting the performance of appropriate treatment, and enhance mutual understanding between patients and healthcare professionals. The guidelines were prepared through the consensus of the JSGO guideline committee, based on a careful review of evidence from the literature searches and the medical health insurance system and actual clinical practice situations in Japan. The main features of the 2023 revision are as follows: 1) The Guidelines Formulation Committee members were asked to understand Minds' medical guideline development method in advance. 2) The clinical question (CQ) was changed to Patient, Intervention, Comparison, Outcome format as much as possible. 3) Introduced the "body of evidence," which summarizes the results of research reports collected for the CQs by outcome and study design, and the strength of evidence for each body of evidence was rated from levels A to D. 4) Introduction of systematic reviews in some CQs. 5) The strength of evidence, the balance of benefits and harms, value and hope for patients, and clinical applicability were considered while drafting recommendations. Herein, we present the English version of the JSGO guidelines 2023 for the treatment of uterine body neoplasm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine NeoplasmsFemaleHumansGynecologyJapanMedical OncologySocieties, MedicalSystematic Reviews as Topic

Stichwörter der Autor:innen

Clinical Practice GuidelineEndometrial CancerGestational Trophoblastic DiseaseSarcomaTreatment

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, School of Medicine, Kyorin University, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, School of Medicine, Kyorin University, Tokyo, Japan. yoichi@ks.kyorin-u.ac.jp.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
  • Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
  • Division of Obstetrics and Gynecology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
  • Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine and Faculty of Medicine, Sapporo, Japan.

ORCID-Profile: Tohru Morisada, Yoichi Kobayashi, Satoru Nagase, Tsukasa Baba, Hideki Tokunaga, Hidemichi Watari, Munetaka Takekuma, Yasuhisa Terao, Yoshito Terai, Hiroaki Kajiyama, Mikiko Asai-Sato, Kazuhiro Takehara, Tsutomu Tabata, Kenichi Harano, Yasuyuki Hirashima, Mayu Yunokawa, Aikou Okamoto, Mikio Mikami

Zitieren

APA

Morisada, T., Kobayashi, Y., Nagase, S., Baba, T., Tokunaga, H., Watari, H., Takekuma, M., Terao, Y., Terai, Y., Kajiyama, H., Asai-Sato, M., Takehara, K., Tabata, T., Harano, K., Hirashima, Y., Yunokawa, M., Okamoto, A., & Mikami, M. (2025). Japan Society of Gynecologic Oncology 2023 guidelines for treatment of uterine body neoplasm. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e119

Vancouver

Morisada T, Kobayashi Y, Nagase S, Baba T, Tokunaga H, Watari H, et al. Japan Society of Gynecologic Oncology 2023 guidelines for treatment of uterine body neoplasm. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e119

BibTeX
@article{Morisada2025,
  author = {Morisada, Tohru and Kobayashi, Yoichi and Nagase, Satoru and Baba, Tsukasa and Tokunaga, Hideki and Watari, Hidemichi and Takekuma, Munetaka and Terao, Yasuhisa and Terai, Yoshito and Kajiyama, Hiroaki and Asai-Sato, Mikiko and Takehara, Kazuhiro and Tabata, Tsutomu and Harano, Kenichi and Hirashima, Yasuyuki and Yunokawa, Mayu and Okamoto, Aikou and Mikami, Mikio},
  title = {Japan Society of Gynecologic Oncology 2023 guidelines for treatment of uterine body neoplasm},
  journal = {Journal of Gynecologic Oncology},
  year = {2025},
  doi = {10.3802/jgo.2025.36.e119}
}
Kostenlos starten →